MedPath

Prospective, European collaborative multicenter observational study of standardized, ontogenetically based radical surgery in endometrial cancer FIGO IAG3 and stage IB to III by peritoneal mesometrial resection and therapeutic lymphadenectomy (PMMR/tLNE) without additional radiotherapy

Recruiting
Conditions
C54
Malignant neoplasm of corpus uteri
Registration Number
DRKS00016541
Lead Sponsor
niversitätsklinikum Essen
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Female
Target Recruitment
500
Inclusion Criteria

Histologically proven endometrial carcinoma: endometroid and non-endometroid FIGO stages I-III; Karnofsky-Index = 70; unrestricted operability; Age >=18 years.
- Completed treatment with according Cohort A, PMMR/targeted compartmental pelvic/paraaortic +/- complete pelvic and paraaortic LNE without adjuvant radiotherapy by the responsible clinic (clinician).
or
- Completed treatment according Cohort B, current clinical practice including adjuvant treatment based on ESMO/ESGO/ESTRO guidelines [26] by the responsible clinic (clinician).
- Informed consent of the patient

Exclusion Criteria

Uterine pure sarcoma
- Distant metastases; sclerodermia, lupus erythematodes, mixed connective tissue disease; secondary malignancy; previous radiotherapy of the pelvis.
- Pregnancy
- Patients with diseases of the connective tissue will be excluded because of unforeseeable (e.g. neurological) symptoms and disorders after surgery.
- Postoperative radiotherapy could be administered with respect to the surgical field in R1 situation or if >= 5 lymph nodes were involved; in all other situations adjuvant radiotherapy will be an exclusion criterion for participation in the study cohort A.

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Progression-free Survival
Secondary Outcome Measures
NameTimeMethod
Overall Survival<br>QOL (EORTC QLQ-C30, SAQ, German Pelvic Floor Questionnaie, Lymphedema-Questionnaire).
© Copyright 2025. All Rights Reserved by MedPath